Talk Bio

Busy FDA gives rare disease sector complementary pathways, unanswered questions – 2026 snapshot

Rare Disease Vouchers Caught in Political Abyss: Recent Updates on Reauthorization Efforts

Fortress Biotech and Sentynl Therapeutics Fail to Secure FDA Approval for CUTX-101 in Rare Pediatric Menkes Disease

FDA Grants Accelerated Approval to Stealth BioTherapeutics’ Forzinity, the First Treatment for Barth Syndrome